Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FOXN3 antisense RNA 1 (FOXN3-AS1)
- Target
- FOXN3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
FOXN3 antisense RNA 1 (FOXN3-AS1) is a long non-coding RNA (lncRNA) located near genomic regions associated with cancer risk, especially in breast cancer and acute myeloid leukemia (AML)[2][4]. FOXN3-AS1 is significantly upregulated in breast cancer tissues compared to normal tissues, with expression levels correlating with tumor size and malignancy, suggesting its use as a diagnostic biomarker[2]. In AML, FOXN3-AS1 shows prognostic significance, and its expression is sensitive to DNMT1 inhibition, implicating it in epigenetic regulatory pathways[4]. Mechanistic data are emerging, but FOXN3-AS1 is not considered a traditional therapeutic target such as a receptor or enzyme; rather, it is an RNA biomolecule with regulatory roles. There are currently no drugs that directly target FOXN3-AS1, but its expression may be modulated indirectly by epigenetic drugs. Further research is required to fully define its molecular roles and potential as a therapeutic or diagnostic target.
- Other names
- FOXN3 antisense RNA 1 (non-protein coding)FOXN3-AS1
02
Mechanism of action
Epigenetic modulation via DNMT1 interaction (proposed/probed in AML[4])
03
Biological functions
Regulation of gene expressionPotential roles in cancer progression (e.g., breast cancer, acute myeloid leukemia)Possible involvement in epigenetic regulation via interaction with DNMT1[4]
04
Disease associations
Cancer (notably breast cancer[2], acute myeloid leukemia[4])
05
Safety considerations
No specific clinical safety/therapeutic concern data available for FOXN3-AS1 itself (as of current search results)
06
Interacting drugs
DNMT1 inhibitors (e.g., 5-azacytidine/5AzaC shown to alter its expression in AML cell lines[4])
07
Biomarkers
Prognostic marker in acute myeloid leukemia (AML)[4]Potential diagnostic biomarker in breast cancer[2]
Beyond the preview
Go deeper on FOXN3 antisense RNA 1 (FOXN3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOXN3 antisense RNA 1 (FOXN3-AS1).